DKCM
ACOR

Davidson Kempner Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Davidson Kempner Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-55,145
Closed -$689K – 328
2024
Q1 		$689K Hold
55,145
– – 0.01% 171
2023
Q4 		$801K Hold
55,145
– – 0.01% 148
2023
Q3 		$750K Hold
55,145
– – 0.01% 153
2023
Q2 		$717K Sell
55,145
-35,009
-39% -$416K 0.01% 165
2023
Q1 		$1.01M Sell
90,154
-29,629
-25% -$492K 0.02% 213
2022
Q4 		$1.82M Hold
119,783
– – 0.03% 255
2022
Q3 		$757K Hold
119,783
– – 0.01% 321
2022
Q2 		$1.11M Buy
+119,783
New +$2.13M 0.02% 322

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Davidson Kempner Capital Management's ACOR Position: Q2 2024 in Review

Davidson Kempner Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 55,145 shares — an estimated $689K sold.

Davidson Kempner Capital Management first reported a position in ACOR in Q2 2022 and held it in 8 quarters. The position peaked at $1.82M in Q4 2022. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Davidson Kempner Capital Management reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 55,145 Acorda Therapeutics shares in Q2 2024, an estimated $689K.
  • Davidson Kempner Capital Management first reported a position in Acorda Therapeutics in Q2 2022 and held it in 8 quarters.
  • Davidson Kempner Capital Management's Acorda Therapeutics position peaked at $1.82M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.